Clinical Trials Browser

Lung Neoplasms

NCT07437963 2026-03-18

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

76 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT02339571 2026-03-17

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Phase 2/3 Active not recruiting

600 enrolled

Dermatologic

Melanoma

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT00026312 2026-03-05

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Phase 3 Completed

1,449 enrolled 17 charts

CNS

Neuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT02455557 2026-02-25

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03794349 2026-02-18

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Phase 2 Active not recruiting

94 enrolled 14 charts

CNS

Neuroblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Phase 2 Recruiting

45 enrolled

CNS

Neuroblastoma

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 1 Completed

19 enrolled

Adenoma, Islet Cell

NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase 2 Completed

34 enrolled 22 charts

Sarcoma

Sarcoma, Alveolar Soft Part

NCT05544968 2026-01-12

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Phase 1 Not yet recruiting

42 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

Clinical Trials

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

PNeoVCA

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies